Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
← Research & Industry News
External source

Beyond Conventional CRISPR

Genome editing is not designed to replace neurons or retinal cells that have already been lost. In this article, experts from four companies—eGenesis, Epicrispr, KOMO Biosciences, and Sumitomo Pharma America—discuss how they are moving beyond conventional CRISPR to develop novel approaches for treating disease.

Published by
GEN — Genetic Engineering & Biotechnology News
Evidence type
Laboratory

Genome editing is not designed to replace neurons or retinal cells that have already been lost. In this article, experts from four companies—eGenesis, Epicrispr, KOMO Biosciences, and Sumitomo Pharma America—discuss how they are moving beyond conventional CRISPR to develop novel approaches for treating disease.

This item was selected automatically by our daily literature and news monitor because it matches the topics we follow. Read the full story at GEN — Genetic Engineering & Biotechnology News.

Gene Delivery & Transfection

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.
Beyond Conventional CRISPR | Brilliant Blue Biosciences